Advancing Cancer Immunotherapy: SON-1010

Frontiers in Immunology

Cytokines have long been recognized for their potential in cancer immunotherapy, but achieving clinical success has remained a challenge.

The recently published research article, “SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy,” represents a significant step forward in cytokine-based therapies.

We’re thrilled to share that LBG’s DJ Rezac contributed to this groundbreaking work, alongside an incredible team of researchers: John Cini, Richard T. Kenney, Susan Dexter, Stephen J. McAndrew, Rukiye-Nazan Eraslan, Rich Brody, Rebecca Boohaker, Susan E. Lapi, and Pankaj Mohan.

This innovative platform offers new hope for advancing cancer treatments by enhancing IL-12 delivery to the tumor microenvironment, improving therapeutic efficacy, and addressing toxicity challenges seen in prior approaches.

Read the full article to learn more about this project and technological approach.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.